For example, Constantinescu et al. reported elevated serum ACE activity in 17 of 75 patients with MS compared with 31 healthy controls, suggesting its involvement as an indicator in disease monitoring and therapeutic efficiency [74]. This evidence concerns the gene ACE and myeloid sarcoma.